Targeting KRAS G12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers.

The KRAS G12D mutation, frequently found in pancreatic cancer, is representative of various challenging cancers and is a crucial target for chemotherapy drug development. Researchers are exploring highly selective and potent small molecule inhibitors of KRAS G12D to meet the needs of patients with this mutation. The Patent Highlight reveals novel compounds capable of inhibiting KRAS G12D proteins, potentially useful in treating KRAS G12D -associated diseases, including cancers.